PTO/SB/08A (08-00)

Approved for use through 10/31/2012, OMB 0651-031
U.S. Patent and Trademank Office: U.S. DEPARTMENT OF COMMERCE
TO persons are required to respond to a cofection of information unless it contains a valid OMB control number.

Substitute for form 1448AVPTO

SEP 1 2 2003

INFORMATION DISCLOSURE STATEMENT BY ARRIVENT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete If Known
Application Number	10/602,214
Filing Date	6/24/03
First Named Inventor	Quan et al.
Group Art Unit	1624
Exeminer Name	Unknown T. TRUONS
Attorney Docket Number	DM-6904 CNT 2

	,			U.S. PATENT DOCUM	MENTS	chan Subclass
Examiner Cite No.		U.S. Peters Doo	ument	Name of Patentes or Applicant	Date of Publication of	1 7
		Number Kind (If knd	Code ² (WII)	of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
TNI	/	5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	514/274
1	/	5,317,103	Α	Merck Sharp & Dohrne Limited	5/31/1994	544/367
	1/_	5,342,851	A	McNell-PPC, Inc.	8/30/1994	514/370
	0	5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	548/281
	1/	5,616,601	_ A	GD Searte & Co	4/1/1997	574 /399
	1/-	5,681,838	A	i Hoechst AG	10/28/1897	514 /307
	1	5,707,998	Α	Eisai Co., Ltd.	1/13/1998	514/259
	0,	6,020,357	Α	DuPont Pharma. Company	2/1/2000	514/406
ΩVI_{-}	V					

				FOREIG	N PATENT DOCU	MENTS		·
Examiner	Cite	Foreign Patent Document #			Name of Patentee	Date of Publication of	Pagas, Columna, Lines,	r
initials* No.1	Office ³	Number ⁴	Kind Code ^s (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T _o	
TMT	/	wo	9402477	Ą	Merck Sharp & Dohme Limited	2/3/1994		
M	√	wo	9514683	A	DuPont Merck Pharma. Company	6/1/1995		
1	✓ ·	wo	9518111	A	DuPont Merck Pharma. Company	7/6/1995		
	V	wo	9628427	A	Bedex Lab., Inc.	9/19/1996	-	
	1	wo	9640143	A	SmithKline Beecham Corporation	12/19/1996		
	V ·	wo	9723212	A _i	DuPont Merck Pharma. Company	7/3/1997		
MY	<i>'</i>	wo	9732583	A.	SmithKline Beecham Corporation	9/12/1997		

Examiner		D-4-	7	
Signature	1/2	Date	7/02/00	
-1811010	000	Considered	1 112810	
	والمراجع المراجع			

EXAMINER: Initial if reference considered, whether or not cliction is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

1. **The property of the patent in the patent of the patent in the patent in

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to persons are required to paspond to a collection of information unless it contains a valid OMB control number. Linder the Peperwork Reduction Act of 1856

Substitute for form 1449A/PTO	(CD)		9	2
INFORMATION STATEMENT BY	2	! - 4		1
INFORMATION	USC	L(JSŲ	迉
STATEMENT BY	Y APH	74	100	ЦĮ

Sheet

(use as many sheets as necessary) of 2

	Compl te if Known
Application Number	10/602,214
Fliing Date	6/24/03
First Named Inventor	Quan tal.
Group Art Unit	1824
Examiner Name	Unknown Tr TRUONZ
Attamos Docket Number	DM-6004 CNT 2

			•		FOREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Foreign Patent Documen		ument.	Nema of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No.1	Office ³	Number ⁴	Kind Code ⁸ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Ta	
11	W	1	EP	234830	A,	E. R. Squibb & Sons, Inc.	9/2/1987	-	
	1	/	EP	236902	A	E. R. Squibb & Sons, Inc.	9/16/1987		
			EP	513387	βB	Otsuka Pharm. Co.	11/19/1992	-	
		1	EP	554829	[{] A	Fujisawa Pharm. Co,	8/11/1993		,
17	W		JP	4247081	Å	Takeda Chem. ind. Ltd.	9/3/1992	Chemical Abstract	
					1			· · · · · · · · · · · · · · · · · · ·	
				ļ	+				 -
		ļ		<u> </u>	<u> </u>				
					4		•		L

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	clude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
TNT		TIDWELL et al. "Diarylamidine derivatives with one or both of the aryl moleties consisting of an indole or indole- like ring. Inhibitors of arginine-specific esteroproteases". J. Med. Chem. (1978), 21(7), 613-623.						
		1						
		ı.						
		h						
		ę .						

Examiner Signature	Mon	Date Considered	7/28/05

^{&#}x27;EXAMINER: Initial if reference considered, whether or not cligiton is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Civel information Officer, U.S. Patent and Tradamark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ease type a plus sign (+) inside this Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PT

SEP 1 2 2003

INFORMATION DESCLOS STATEMENT BY

(use as many sheets as necessary)

	Complete if Known
Application Number	10/602,214
Filing Date	6/24/03
First Named Inventor	Quan et al.
Group Art Unit	
Examiner Name	Unknown
Attorney Docket Number	DM-6904 CNT 2

				U.S. PATENT DOCU	MENTS	
		U.S. Patent Doc	ument	Name of Patentee or Applicant	Date of Publication et	Pages, Columns, Lines, Where Retevant
Examiner Initials *	Cite No.	Number Kind Code ² (if known)		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
		5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	
		5,317,103	Α	Merck Sharp & Dohme Limited	5/31/1994	
		5,342,851	Α	McNeil-PPC, Inc.	8/30/1994	
. /		5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	
/		5,616,601	Α	GD Searle & Co	4/1/1997	
		5,681,838	Α	HoechstAG	10/28/1997	
		5,707,998	Α	Eisai Co., Ltd.	1/13/1998	
		6,020,357	Α	DuPont Pharma. Company	2/1/2000	

				FØREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Office ³	eign Patent Docu	ment ind Code ⁵ if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994	·	
		wo	9514683	А	DuPont Merck Pharma. Company	6/1/1995		
		wo/	9518111	A	DuPont Merck Pharma. Company	7/6/1995		·
		wo	9628427	Α	Berlex Lab., Inc.	9/19/1996		
		wo	9640143	Α	SmithKline Beecham Corporation	12/19/1996	·	
		wo	9723212	· A	DuPont Merck Pharma. Company	7/3/1997		
		wo	9732583	Α	SmithKline Beecham Corporation	9/12/1997		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTQ

INFORMATION BISC STATEMENT BY

(use as many sheets as necessary)

2 Sheet 2 of

	Complete if Known
Application Number	10/602,214
Filing Date	6/24/03
First Named Inventor	Quan et al.
Group Art Unit	1624
Examiner Name	Unknown
Attorney Docket Number	DM-6904 CNT 2

				FOREIGI	N PATENT DOCU	MENTS		
Examiner	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
		EP	234830	Α	E. R. Squibb & Sons, Inc.	9/2/1987		
		EP	236902	Α	E. R. Squibb & Sons, Inc.	9/16/1987		
		EP	513387	8	Otsuka Pharm, Co.	11/19/1992		
/		EP	554829	Α	Fujisawa Pharm. Co.	8/11/1993		
		JP	4247081	Α	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
				 	<u>/</u>	· - · · · - · · · · · · · · · · · · · ·		
		 	 	 				
	<u> </u>	 		1/		-		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		TIDWELL et al. *Diarylamidine derivatives with one or both of the aryl moleties consisting of an indole- like ring inhibitors of arginine-specific esteroproteases*. J. Med. Chem. (1978), 21(7), 613-623.	
	/		
/			
		·	

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

through 10/31/2002. OMB 0651-0031

Please type a plus sign (+) inside this box

U.S. Patent and Traden are required to respond to a collection of into

PTO/SB/08A (08-00) or use through 10/31/2002. OMB 0651-0031 Office: U.S. DEPARTMENT OF COMMERCE ation unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPEIDANTS

(use as many sheets as necessary)

Sheet of

	sale a valid CMB control number.					
A	Complete If Known	A				
Application Number	09/924,381					
Filing Date	8/8/2001					
First Named Inventor		40				
Group Art Unit	Lam et al.	P				
Examiner Name	1624	Ch				
Attorney Docket Number	Unknown	W/A				
accuse Manubel	DM-6904-A	- (XX)				

caminer	Cite	U.S. Patent Do		U.S. PATENT DOCUM	VIENTS	
initiats •	No.'		Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Rele
M		5,202,330	A	E. R. Squibb & Sons,	MM-DD-YYYY	Passages or Relevant Class Figures Appear Sub
1			 		4/13/1993	
1-1	-	5,317,103	A	Merck Sharp & Dohme Limited	5/31/1994	514/274
1 - 	-V.	5,342,851	Α	McNeil-PPC, Inc.		544/367
	/	5,463,071	A	Dr. Karl Thomae	8/30/1994	574/370
╂┷┵	1	5,616,601	Α	GMbH	10/31/1995	548/251
├─┼	-/-	5,681,838	Α	GD Searle & Co Hoechst AG	4/1/1997	5/4/399
 	-	5,707,998	Α	Eisai Co., Ltd.	10/28/1997	5/4 /309
V7	V	6,020,357	A	DuPont Pharma.	1/13/1998	514 1259
				Company	2/1/2000	514/406

Examiner Initials* Cite No.1			oreign Patent Do	FOREIC	ON PATENT DOCL	MENTS			
		No.1	Office ³		Kind Code ⁵ (if known)	Name of Patenton	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	V 1	1	Wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994	Figures Appear	T ₆
-		V	wo	9514683	A	DuPont Merck Pharma. Company	6/1/1995		
-	-	V	WO	9518111	A	DuPont Merck Pharma. Company	7/6/1995		
\dashv	+	V	wo	9628427	Α	Berlex Lab., Inc.	9/19/1996		
\dashv	4	/	wo	9640143	Α	SmithKline Beecham Corporation	12/19/1996		
1	1	V	WO	9723212	A	DuPont Merck Pharma.	7/3/1997		
M	1		wo	9732583	A	Company SmithKline Beecham Corporation	9/12/1997		

	1 Corp	oration		- 1
Examiner				ı
Signature	211			
C. C		Date		
EXAMINER: Initial	if reference considered, whether or not citation is in conformal	Considered	#/1/ -	
considered, include	considered, whether or not citation to		7/40V	
	outly of this form with next community of the conformation of the	TCA With MPED con -		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. * Applicant is to place a check mark hee if English language Translation is attached.